{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:59:32Z","timestamp":1791849572562,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/nrgastro.2014.185","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T10:38:49Z","timestamp":1414492729000},"page":"7-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The gut is a key target of therapy in hepatic encephalopathy"],"prefix":"10.1038","volume":"12","author":[{"given":"Rohit","family":"Sawhney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Jalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"BFnrgastro2014185_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2013.10.004","volume":"60","author":"J Cordoba","year":"2014","unstructured":"Cordoba, J.  et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J. Hepatol. 60, 275\u2013281 (2014).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2014185_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau, R.  et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426\u20131437 (2013).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2014185_CR3","doi-asserted-by":"publisher","unstructured":"Rahimi, R. S., Singal, A. G., Cuthbert, J. A. & Rockey, D. C. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern. Med. \n                    http:\/\/dx.doi.org\/10.1001\/jamainternmed.2014.4746\n                    \n                  .","DOI":"10.1001\/jamainternmed.2014.4746"},{"key":"BFnrgastro2014185_CR4","doi-asserted-by":"crossref","unstructured":"American Association for the Study of Liver Disease & European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J. Hepatol. 61, 642\u2013659 (2014).","DOI":"10.1016\/j.jhep.2014.05.042"},{"key":"BFnrgastro2014185_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass, N. M.  et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071\u20131081 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2014185_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/ajg.2013.219","volume":"108","author":"BC Sharma","year":"2013","unstructured":"Sharma, B. C.  et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am. J. Gastroenterol. 108, 1458\u20131463 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2014185_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","volume":"26","author":"E Huang","year":"2007","unstructured":"Huang, E., Esrailian, E. & Spiegel, B. M. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy\u2014a decision analysis. Aliment. Pharmacol. Ther. 26, 1147\u20131161 (2007).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2014185_CR8","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/ajg.2009.160","volume":"104","author":"T Hassanein","year":"2009","unstructured":"Hassanein, T.  et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am. J. Gastroenterol. 104, 1392\u20131400 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2014185_CR9","doi-asserted-by":"publisher","unstructured":"Romero-Gomez, M., Montagnese, S. & Jalan, R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute on chronic liver failure. J. Hepatol. \n                    http:\/\/dx.doi.org\/10.1016\/j.jhep.2014.09.005\n                    \n                  .","DOI":"10.1016\/j.jhep.2014.09.005"},{"key":"BFnrgastro2014185_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/hep.21838","volume":"46","author":"W Bernal","year":"2007","unstructured":"Bernal, W.  et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 46, 1844\u20131852 (2007).","journal-title":"Hepatology"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2014.185","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2014.185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2014.185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:50:49Z","timestamp":1684468249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2014.185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,28]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFnrgastro2014185"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2014.185","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,28]]},"assertion":[{"value":"28 October 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J. declares that he has been a consultant for Conatus Pharmaceuticals and Ocera Therapeutics Inc. He has collaborated on research with funding from research grants from Gambro, Grifols Inc., Norgine, Sequana Medical and Ocera Therapeutics. He has received speaker fees from Grifols Inc. and Norgine. He is the inventor of Ornithine Phenylacetate, which is licensed by UCL to Ocera Therapeutics. R.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}